Introduction: Acute kidney injury (AKI) is significant problem in children with congenital heart disease (CHD) who undergo cardiac surgery. The economic impact of a biomarker-based diagnostic strategy for AKI in pediatric populations undergoing CHD surgery is unknown. The aim of this study was to perform the cost effectiveness analysis of using serum cystatin C (sCysC), urine neutrophil gelatinase-associated lipocalin (uNGAL) and urine liver fatty acid-binding protein (uL-FABP) for the diagnosis of AKI in children after cardiac surgery compared with current diagnostic method (monitoring of serum creatinine (sCr) level). Materials and methods: We developed a decision analytical model to estimate incremental cost-effectiveness of different biomarker-based diagnostic strategies compared to current diagnostic strategy. The Markov model was created to compare the lifetime cost associated with using of sCysC, uNGAL, uL-FABP with monitoring of sCr level for the diagnosis of AKI. The utility m...easurement included in the analysis was quality-adjusted life years (QALY). The results of the analysis are presented as the incremental cost-effectiveness ratio (ICER). Results: Analysed biomarker-based diagnostic strategies for AKI were cost-effective compared to current diagnostic method. However, uNGAL and sCys C strategies yielded higher costs and lower effectiveness compared to uL-FABP strategy. uL-FABP added 1.43 QALY compared to current diagnostic method at an additional cost of $8521.87 per patient. Therefore, ICER for uL-FABP compared to sCr was $5959.35/QALY. Conclusions: Our results suggest that the use of uL-FABP would represent cost effective strategy for early diagnosis of AKI in children after cardiac surgery.
Keywords:
acute kidney injury / cardiac surgery / children / biomarkers / cost effectiveness analysis
TY - JOUR
AU - Petrović, Stanislava
AU - Bogavac-Stanojević, Nataša
AU - Lakić, Dragana
AU - Peco-Antić, Amira
AU - Vulicević, Irena
AU - Ivanišević, Ivana
AU - Kotur-Stevuljević, Jelena
AU - Jelić-Ivanović, Zorana
PY - 2015
UR - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2467
AB - Introduction: Acute kidney injury (AKI) is significant problem in children with congenital heart disease (CHD) who undergo cardiac surgery. The economic impact of a biomarker-based diagnostic strategy for AKI in pediatric populations undergoing CHD surgery is unknown. The aim of this study was to perform the cost effectiveness analysis of using serum cystatin C (sCysC), urine neutrophil gelatinase-associated lipocalin (uNGAL) and urine liver fatty acid-binding protein (uL-FABP) for the diagnosis of AKI in children after cardiac surgery compared with current diagnostic method (monitoring of serum creatinine (sCr) level). Materials and methods: We developed a decision analytical model to estimate incremental cost-effectiveness of different biomarker-based diagnostic strategies compared to current diagnostic strategy. The Markov model was created to compare the lifetime cost associated with using of sCysC, uNGAL, uL-FABP with monitoring of sCr level for the diagnosis of AKI. The utility measurement included in the analysis was quality-adjusted life years (QALY). The results of the analysis are presented as the incremental cost-effectiveness ratio (ICER). Results: Analysed biomarker-based diagnostic strategies for AKI were cost-effective compared to current diagnostic method. However, uNGAL and sCys C strategies yielded higher costs and lower effectiveness compared to uL-FABP strategy. uL-FABP added 1.43 QALY compared to current diagnostic method at an additional cost of $8521.87 per patient. Therefore, ICER for uL-FABP compared to sCr was $5959.35/QALY. Conclusions: Our results suggest that the use of uL-FABP would represent cost effective strategy for early diagnosis of AKI in children after cardiac surgery.
PB - Croatian Soc Medical Biochemists, Zagreb
T2 - Biochemia Medica
T1 - Cost-effectiveness analysis of acute kidney injury biomarkers in pediatric cardiac surgery
VL - 25
IS - 2
SP - 262
EP - 271
DO - 10.11613/BM.2015.027
ER -
@article{
author = "Petrović, Stanislava and Bogavac-Stanojević, Nataša and Lakić, Dragana and Peco-Antić, Amira and Vulicević, Irena and Ivanišević, Ivana and Kotur-Stevuljević, Jelena and Jelić-Ivanović, Zorana",
year = "2015",
abstract = "Introduction: Acute kidney injury (AKI) is significant problem in children with congenital heart disease (CHD) who undergo cardiac surgery. The economic impact of a biomarker-based diagnostic strategy for AKI in pediatric populations undergoing CHD surgery is unknown. The aim of this study was to perform the cost effectiveness analysis of using serum cystatin C (sCysC), urine neutrophil gelatinase-associated lipocalin (uNGAL) and urine liver fatty acid-binding protein (uL-FABP) for the diagnosis of AKI in children after cardiac surgery compared with current diagnostic method (monitoring of serum creatinine (sCr) level). Materials and methods: We developed a decision analytical model to estimate incremental cost-effectiveness of different biomarker-based diagnostic strategies compared to current diagnostic strategy. The Markov model was created to compare the lifetime cost associated with using of sCysC, uNGAL, uL-FABP with monitoring of sCr level for the diagnosis of AKI. The utility measurement included in the analysis was quality-adjusted life years (QALY). The results of the analysis are presented as the incremental cost-effectiveness ratio (ICER). Results: Analysed biomarker-based diagnostic strategies for AKI were cost-effective compared to current diagnostic method. However, uNGAL and sCys C strategies yielded higher costs and lower effectiveness compared to uL-FABP strategy. uL-FABP added 1.43 QALY compared to current diagnostic method at an additional cost of $8521.87 per patient. Therefore, ICER for uL-FABP compared to sCr was $5959.35/QALY. Conclusions: Our results suggest that the use of uL-FABP would represent cost effective strategy for early diagnosis of AKI in children after cardiac surgery.",
publisher = "Croatian Soc Medical Biochemists, Zagreb",
journal = "Biochemia Medica",
title = "Cost-effectiveness analysis of acute kidney injury biomarkers in pediatric cardiac surgery",
volume = "25",
number = "2",
pages = "262-271",
doi = "10.11613/BM.2015.027"
}
Petrović, S., Bogavac-Stanojević, N., Lakić, D., Peco-Antić, A., Vulicević, I., Ivanišević, I., Kotur-Stevuljević, J.,& Jelić-Ivanović, Z.. (2015). Cost-effectiveness analysis of acute kidney injury biomarkers in pediatric cardiac surgery. in Biochemia Medica
Croatian Soc Medical Biochemists, Zagreb., 25(2), 262-271.
https://doi.org/10.11613/BM.2015.027
Petrović S, Bogavac-Stanojević N, Lakić D, Peco-Antić A, Vulicević I, Ivanišević I, Kotur-Stevuljević J, Jelić-Ivanović Z. Cost-effectiveness analysis of acute kidney injury biomarkers in pediatric cardiac surgery. in Biochemia Medica. 2015;25(2):262-271.
doi:10.11613/BM.2015.027 .
